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Prophylactic
Antibiotic
Conventional
Antibiotics
P
value
Total Number of Patients 36 37
Autologous 10 14
Allogeneic Cord Blood 10 9
Allogeneic Bone Marrow 16 14
Positive Blood Cultures 28 29
Gram Positive Total (#Patients) 24 (7) 27 (10)
Gram Negative Total (#Patients) 5 (1) 2 (2)
Mean Discharge Day 43.29 34.74 0.13
Autologous 23.40 18.73 0.99
Allogeneic Cord Blood 62.50 52.80 0.27
Allogeneic Bone Marrow 43.20 35 0.80
Days of Fever 8.71 11.31 0.28
Autologous 7.89 6.46 0.70
Allogeneic 9.72 14.32 0.14
PICU Admission 7 3
Need for Pressors 3 3
Clostridium difﬁcile Diarrhea 6 4
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received melphalan 200 mg/m2. The incidence and grade of
OM were assessed in both groups using the WHO grading
system.
Results: A total of 247 consecutive patients were identiﬁed.
In the FBT cohort, 26 patients received SCPR and 122 pa-
tients received palifermin for OM prophylaxis. In the
Melphalan cohort, 68 patients received SCPR and 31 pa-
tients received palifermin for OM prophylaxis. In the FBT
cohort, the incidence of grade 3 or 4 OM was signiﬁcantly
lower in the palifermin compared to SCPR group (57% vs
100%, OR¼0.19, p<0.0001). The overall incidence of OMwas
lower in the palifermin compared to SCPR group (86% vs
100%, OR¼0.42, p¼0.06). In the melphalan cohort, the
incidence of grade 3 or 4 OM was signiﬁcantly lower in the
SCPR compared to the palifermin group (12% vs 35%,
OR¼0.24, p¼0.008). The overall incidence of OM was lower
in the SCPR compared to the palifermin group (28% vs 58%,
OR¼0.28, p¼0.005).
Conclusion: While palifermin is more effective than SCPR in
preventing FBT-induced OM, SCPR appears more effective in
preventingmelphalan-induced OM. These ﬁndings challenge
the current accepted biological model that views OM as a
universal outcome regardless of the causative agent. We
propose individualized selection of OM prophylactic agent
based on the type of conditioning therapy.293
Prophylactic Broad Spectrum Antibiotics at the Onset of
Neutropenia in HSCT Do Not Change the Number of
Febrile Days or Duration of Hospitalization
Hilary Haines. Pediatrics, Division of Pediatric Hematology/
Oncology, University of Alabama Birmingham, Birmingham, AL
There is increased interest in the use of broad spectrum an-
tibiotics at the onset of neutropenia during hematopoietic
stem cell transplant to prevent serious bacterial infections. In
2009, our group instituted the use of cefepime starting when
the ANC decreased to < 500 as one quality improvement
measure to help reduce the number of serious bacterial in-
fections. This is a preliminary analysis on the efﬁcacy of this
intervention.
All patients undergoing a hematopoietic stem cell trans-
plant from January 2008 to December 2011 were included in
this retrospective analysis. Assignment of patients to each
group was based on intent to treat with 36 patients to have
broad spectrum antibiotic initiated at the onset of neu-
tropenia or with fevers (prophylactic antibiotic group) and
37 patients had antibiotics initiated only for febrile episodes
(conventional antibiotic group). There was no difference
between the two groups in days post transplant for
discharge and number of days of fever. There was a trend
towards a decreased number of febrile days in allogeneic
patients only although this was not statistically signiﬁcant.
8 patients in the prophylactic antibiotic group and 11 pa-
tients conventional antibiotic group had positive blood
culture results at some point during their immediate post-
transplant courses, the majority of which were gram posi-
tive infections. There were 3 deaths prior to hospital
discharge in the conventional antibiotic group, one of sepsis
secondary to vancomycin resistant enterococcus and the
remaining 2 died of respiratory failure due to pulmonary
hemorrhage. There was one death of pulmonary hemor-
rhage associated with refractory GVHD in the prophylactic
antibiotic group.
Despite the fact that there was a decrease in the number of
patients with bacterial infections, preliminary data from thispatient population does not yet indicate an overwhelming
improvement in patient outcomes following the use of pro-
phylactic cefepime at the onset of neutropenia, perhaps due
to the relative infrequency of gram negative bacterial in-
fections. Additional information in a larger number of pa-
tients, including patterns of antibiotic resistance and
duration of antibiotics, may help to deﬁne whether prophy-
lactic antibiotics initiated at the onset of neutropenia change
outcomes.294
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Respiratory virus infections are recognized as an important
complication in hematopoietic stem cell transplantation
(HSCT). Respiratory syncytial virus (RSV), inﬂuenza, and
parainﬂuenza have been associated with high morbidity and
mortality post HSCT. Despite an increasing number of re-
ports, knowledge regarding risk factors and long term pul-
monary complications are still very limited. Therefore, we
report our study to evaluate incidence and outcome of res-
piratory virus infections following HSCT in a large pediatric
transplant centre.
Eight hundred and forty four children received HSCT during
the study period (January 2000 and August 2012). The
number of patients undergoing allogeneic (allo) transplant
was 489 and autologous (auto) was 355. Thirty-ﬁve patients
(4.2%) were found to have respiratory virus infection diag-
nosed by a nasopharyngeal aspirate (NPA) in the ﬁrst
100 days post HSCT. Among these, 22 (63%) and 13 (37%)
were allo and auto HSCT recipients, respectively. Upper and
lower respiratory tract infection were documented in 19
(54.3%) and 16 (45.7%) patients, respectively. The viruses
identiﬁed were parainﬂuenza 37%, inﬂuenza 26%, RSV 23%,
adenovirus 11%, and human metapneumovirus 3%. None of
the patients had signiﬁcant respiratory symptoms prior to
HSCT.
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from outcome analysis. Of the remaining 28 patients, ﬁve
HSCT recipients (4 allo and 1 auto) have died (18%). All pa-
tients who died were in the lower respiratory tract infection
group and their death was directly attributed to pulmonary
complications as a result of respiratory virus infections. Two
patients died from adenovirus pneumonitis and ARDS. Two
patients died from severe parainﬂuenza infection with
deterioration of symptoms and respiratory failure despite
treatment with ribavarin and the last patient had ARDS from
RSV infection. No chronic pulmonary complication or allo-
immune lung syndrome was observed among the remaining
23 survivors with a median follow-up time of 3.8 years (8
months-10.3 years).
This study supports the signiﬁcant TRM from respiratory
virus infection diagnosed within the ﬁrst 100 days post HSCT
particularly in patients presented with lower respiratory
tract infection. Higher mortality was observed among allo
recipients. Every effort should be made to prevent respira-
tory virus infections early post HSCT.295
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Introduction: Falls are a common cause of morbidity and
mortality among hospitalized patients in the United States.
Patients with cancer are vulnerable to falls with injury as a
result of complex medical regimens, impaired performance
status, and chemotherapy toxicities such as neuropathy.
Predictors of falls in the general oncology population
include abnormal gait, presence of metastasis, antide-
pressant and antipsychotic medication use, and blood
product use. Risk factors for falls in the hematopoietic
stem cell transplant (HSCT) population are not as well
understood.
Methods: We performed a retrospective review of patients
admitted to Dana-Farber/Brigham and Women’s Cancer
Center from 01/2011 to 12/2012, who had a fall during their
admission to a HSCT service. Patients were classiﬁed as either
fall or fall with injury (FWI). Our primary objective was to
describe characteristics of hospitalized HSCT patients who
experience a FWI, including medications administered in the
24 hours prior to the fall.
Results: There were 91 falls identiﬁed in 81 patients. One
patient was excluded from the analysis due to incomplete
electronic medical records. Nine patients had more than
one fall. Thirty-two falls resulted in FWI. Fifty-seven falls
(62.6%) occurred during an index admission for HSCT. This
represents 5.48% of our index admissions. Patients had a
history of HSCT or were undergoing myeloablative HSCT
(n¼25), reduced intensity conditioning HSCT (n¼19) or
autologous HSCT (n¼36). Patient and transplant character-
istics were compared between patients who had falls
without injury and patients who had FWI. There was no
signiﬁcant difference in age (p¼0.99), gender (p¼0.65),
cancer diagnosis (p¼0.84), hospital admission team
(p¼0.99), admission type (p¼0.14) or transplant type
(p¼0.80) between patients with falls and FWI. Inmultivariate analysis, benzodiazepine use (p¼0.016) and
Morse Fall score  45 (p¼0.031) were associated with
increased risk of FWI, whereas diuretic use (p¼0.029),
presence of heart disease (p¼0.023) and prior fall (p¼0.015)
were associated with decreased risk of FWI.
Conclusions: Falls are common in patients hospitalized for
HSCT. Benzodiazepine use and high Morse Fall score predict
for an increased risk of injury after a fall event. Adequate
assessment and management of these modiﬁable fall risk
factors, including decreasing our benzodiazepine use and
early identiﬁcation of at risk patients may help prevent FWI
in our HSCT population.296
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Respiratory syncytial virus (RSV) in the immunocompromised
adult can lead to signiﬁcant morbidity and mortality. Most
immunocompromised patients with RSV pneumonia present
to a health care facility with an upper respiratory tract infec-
tionw1 week prior to the onset of pneumonia. Overall, 40%e
50% of RSV upper respiratory tract infections (URTI) in HCT
recipients will progress to pneumonia. RSV pneumonia in HCT
recipients is associated with fatality rates as high as 70e80%.
Treatment of RSV pneumonia is primarily supportive. The role
of speciﬁc antiviral therapy remains uncertain. We retro-
spectively reviewed RSV-infected patients with upper or
lower respiratory tract infection (LRTI) diagnosed by antigen
testing, polymerase chain reaction and/or culture from
January 2007 through March 2013. In general, clinically stable
URTI patients with an absolute lymphocyte count (ALC)> 300
received only supportive care. Patients presenting with URTI
and lymphopenia (ALC  300) were preferentially treated
with a course of inhaled ribavirin (IR) alone. Those presenting
with LRTI were preferentially treated with IR in combination
with the RSV-speciﬁc humanized monoclonal antibody, Pal-
ivizumab. We identiﬁed 60 consecutive patients who were
diagnosed with RSV (median age 52 [21 - 72]) - 35 had URTI
and 25 had LRTI. Forty-one (71%) of the patients had received
an allogeneic transplant, seven (12%) were post autologous
transplant, while 10 (17%) were receiving treatment for acute
leukemia. Of the allogeneic transplant patients, 31 (51.6 %)
were receiving immunosuppressants and 24 (40%) were being
